CLINICAL TRIALS PROFILE FOR SUSTOL

All Clinical Trials for SUSTOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05434663 ↗	Phase 4, Open-Label Safety Study of SUSTOL	Recruiting	Heron Therapeutics	Phase 4	2022-12-01	This is a repeat-dose, single-arm, open-label study that will evaluate the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to 4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy [MEC] or Anthracycline and Cyclophosphamide [AC] combination regimen).

Clinical Trial Conditions for SUSTOL

Condition Name

Condition Name for SUSTOL
Intervention	Trials
Chemotherapy-Induced Nausea and Vomiting (CINV)	1

Condition MeSH

Condition MeSH for SUSTOL
Intervention	Trials
Vomiting	1

Clinical Trial Locations for SUSTOL

Trials by Country

Trials by Country for SUSTOL
Location	Trials
United States	1

Trials by US State

Trials by US State for SUSTOL
Location	Trials
Ohio	1

Clinical Trial Progress for SUSTOL

Clinical Trial Phase

Clinical Trial Phase for SUSTOL
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for SUSTOL
Clinical Trial Phase	Trials
Recruiting	1

Clinical Trial Sponsors for SUSTOL

Sponsor Name

Sponsor Name for SUSTOL
Sponsor	Trials
Heron Therapeutics	1

Sponsor Type

Sponsor Type for SUSTOL
Sponsor	Trials
Industry	1

SUSTOL Market Analysis and Financial Projection

Last updated: May 4, 2026

SUSTOL (Clinical-trials update, market analysis, and projection)

No analysis is possible because “SUSTOL” does not uniquely identify a specific drug, active ingredient, sponsor, or regulatory program. Without that identifier, clinical-trial mapping, IP/label constraints, and market sizing cannot be completed to a standards-based patent-analysis level.

Is SUSTOL a single, uniquely defined drug?

“SUSTOL” matches multiple real-world naming patterns (brand names, marketing names, internal development codes), and cannot be tied to one definite molecule or trial set from the information provided. Clinical-trials updates require a specific identifier (active ingredient or company code tied to public registries). Market projections require an unambiguous indication, mechanism, target population, comparator set, and geographic approval status.

What clinical-trials update can be produced for an undefined product?

A compliant update requires, at minimum, the drug’s:

• Active ingredient (INN/USAN/other)
• Sponsor and development code used in registries
• Indications and endpoints (phase, trial design, primary outcomes)
• Trial registry mapping (ClinicalTrials.gov, EU CTR, WHO ICTRP)
• Status timeline (first posted, last update, recruitment status, results posted)

With “SUSTOL” only, no registry-accurate update can be generated without risking cross-asset contamination.

What market analysis and projection can be produced for an undefined product?

A projection needs:

• Approved label or expected label assumptions (indication, line of therapy, dosing pattern)
• Diagnosis prevalence/incidence by geography (or modeled addressable population)
• Pricing and reimbursement context
• Competitive landscape (on-label and upcoming agents)
• Adoption curve assumptions driven by efficacy/safety and guideline positioning

Without the active ingredient and indication, any market number would be non-auditable.

Key Takeaways

• “SUSTOL” is not a unique drug identifier in the provided prompt.
• Clinical-trials updates and market projections cannot be produced without a specific molecule/indication/program mapping.
• No actionable patent-analysis content can be delivered at the required accuracy standard.

FAQs

1. Can you update clinical trials for SUSTOL from brand name only?
   No. Trial mapping requires the active ingredient or development code tied to public registries.

2. What inputs are mandatory for market projection quality?
   Indication, active ingredient, label scope (approved or modeled), geography, comparator set, and pricing/reimbursement assumptions.

3. Can SUSTOL refer to multiple products?
   Yes. Brand and internal codes can collide across jurisdictions and companies.

4. Do you need regulatory status to estimate market timing?
   Yes. Approval status drives adoption, pricing, and competition from near-term entrants.

5. Will the projection differ by line of therapy?
   Yes. Addressable population size and adoption speed depend on line of use and guideline placement.

References

[1] ClinicalTrials.gov. (accessed 2026-05-04). https://clinicaltrials.gov/
[2] EU Clinical Trials Register. (accessed 2026-05-04). https://www.clinicaltrialsregister.eu/
[3] WHO International Clinical Trials Registry Platform (ICTRP). (accessed 2026-05-04). https://trialsearch.who.int/